Health Care [ 4/12 ] | Health Care Providers & Services [ 28/72 ]
NYSE | Common Stock
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development.
The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings.
In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access.
It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories.
The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 25, 24 | 3.94 Increased by +3.68% | 3.80 Increased by +3.68% |
| Apr 25, 24 | 3.68 Decreased by -3.66% | 3.48 Increased by +5.75% |
| Feb 15, 24 | 3.30 Decreased by -20.29% | 3.26 Increased by +1.23% |
| Oct 26, 23 | 3.38 Decreased by -27.78% | 3.33 Increased by +1.50% |
| Jul 27, 23 | 3.80 Decreased by -23.23% | 3.53 Increased by +7.65% |
| Apr 25, 23 | 3.82 Decreased by -37.48% | 3.96 Decreased by -3.54% |
| Feb 16, 23 | 4.14 Decreased by -38.85% | 4.10 Increased by +0.98% |
| Oct 27, 22 | 4.68 Decreased by -31.38% | 4.67 Increased by +0.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 3.06 B Decreased by -15.23% | 183.30 M Decreased by -48.04% | Increased by +6.00% Decreased by -38.71% |
| Jun 30, 23 | 3.03 B Decreased by -17.94% | 188.90 M Decreased by -47.32% | Increased by +6.23% Decreased by -35.81% |
| Mar 31, 23 | 3.78 B Decreased by -3.12% | 212.90 M Decreased by -56.69% | Increased by +5.64% Decreased by -55.30% |
| Dec 31, 22 | 3.67 B Decreased by -9.42% | 76.10 M Decreased by -86.24% | Increased by +2.07% Decreased by -84.81% |
| Sep 30, 22 | 3.61 B Decreased by -11.24% | 352.80 M Decreased by -39.93% | Increased by +9.78% Decreased by -32.32% |
| Jun 30, 22 | 3.70 B Decreased by -3.74% | 358.60 M Decreased by -23.28% | Increased by +9.70% Decreased by -20.29% |
| Mar 31, 22 | 3.90 B Decreased by -6.29% | 491.60 M Decreased by -36.12% | Increased by +12.61% Decreased by -31.83% |
| Dec 31, 21 | 4.06 B Decreased by -9.66% | 553.00 M Decreased by -41.06% | Increased by +13.63% Decreased by -34.76% |